Kratom

Phase 1Small molecule

AAltasciences Company Inc.

Kratom is one of 2 small molecule programs targeting Opioid Use. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Opioid UseNot yet recruiting

Opioid UsePhase 1

Not yet recruiting

Competition

Competitive Landscape

1 competitor in Opioid Use

#DrugCompanyPhaseTrials

Bupivacaine-Epinephrine

UUniversity of Aarhus

Phase 3

1 2

Kratom

AAltasciences Company Inc.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2029

Phase 1Not yet recruiting

Opioid Use

NCT07218549

Clinical

Trials by Indication[1]

Single Ascending Dose1 trial

Single Ascending Doses of Kratom in Healthy Nondependent Adults With Opioid Experience

Completed·AAltasciences Company Inc.·Phase 1·NCT06072170·40 enrolled

Opioid Use1 trial

Evaluation of the Safety and Effects of Psychoactive Substances in People With Past Opioid Use

Not yet recruiting·CChristopher D. Verrico·Phase 1·NCT07218549·72 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Kratom. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Kratom compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Kratom. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Altasciences Company Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: AAltasciences Company Inc.

Kratom

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2029

Trials by Indication[1]

Single Ascending Dose1 trial

Opioid Use1 trial

References

Drug Info

Quick Facts

Related News